In vivo comparison of the bone regeneration capability of human bone marrow concentrates vs. platelet-rich plasma.
In vivo comparison of the bone regeneration capability of human bone marrow concentrates vs. platelet-rich plasma.
复制标题
DOI：
10.1371/journal.pone.0040833
复制
发表时间：
2012
期刊：
影响因子：
3.7
通讯作者：
Asahina I
中科院分区：
文献类型：
--
作者：
Zhong W;Sumita Y;Ohba S;Kawasaki T;Nagai K;Ma G;Asahina I
与富含生长因子的富血小板血浆（PRP）相比，包含高密度干细胞和祖细胞的骨髓抽吸浓缩物（BMAC）可能具有更强的骨再生能力。本研究旨在评价人BMAC和PRP联合β-磷酸三钙（β-TCP）对免疫缺陷小鼠模型中初始骨增量的促进作用。使用自动血液分离器从骨髓和外周血抽吸物中浓缩BMAC和PRP。采用β-TCP颗粒作为支架来携带细胞。在细胞计数和FACS表征后，三组裸鼠（BMAC+TCP、PRP+TCP和TCP对照）植入移植物材料，用于在颅骨上贴附放置。4周后收获样品，并制备连续切片。光镜下观察新生骨的形态，并进行形态计量学分析。离心后，BMAC中有核细胞和血小板的浓度分别增加了2.8±0.8和5.3±2.4倍，而PRP中白细胞和血小板的浓度分别增加了4.1±1.8和4.4±1.9倍。在BMAC和PRP中，CD 34-、CD 271-、CD 90-、CD 105-和CD 146-阳性细胞的浓度均显著增加。BMAC组和PRP组的新骨形成率分别为7.6±3.9%和7.2±3.8%，显著高于TCP组的2.7±1.4%。BMAC和PRP联合移植的新骨中骨细胞数（552±257）和（491±211）明显多于单纯TCP（187±94）。但治疗组间差异不显著。人BMAC和PRP两者都可以在骨组织工程应用中提供治疗益处。这些组分具有类似的增强早期骨再生的能力。
Bone marrow aspirate concentrate (BMAC) including high densities of stem cells and progenitor cells may possess a stronger bone regenerative capability compared with Platelet-rich plasma (PRP), which contains enriched growth factors. The objective of this study was to evaluate the effects of human BMAC and PRP in combination with β-tricalcium phosphate (β-TCP) on promoting initial bone augmentation in an immunodeficient mouse model. BMAC and PRP were concentrated with an automated blood separator from the bone marrow and peripheral blood aspirates. β-TCP particles were employed as a scaffold to carry cells. After cell counting and FACS characterization, three groups of nude mice (BMAC+TCP, PRP+TCP, and a TCP control) were implanted with graft materials for onlay placement on the cranium. Samples were harvested after 4 weeks, and serial sections were prepared. We observed the new bone on light microscopy and performed histomorphometric analysis. After centrifugation, the concentrations of nucleated cells and platelets in BMAC were increased by factors of 2.8±0.8 and 5.3±2.4, respectively, whereas leucocytes and platelets in PRP were increased by factors of 4.1±1.8 and 4.4±1.9, respectively. The concentrations of CD34-, CD271-, CD90-, CD105-, and CD146-positive cells were markedly increased in both BMAC and PRP. The percentage of new bone in the BMAC group (7.6±3.9%) and the PRP group (7.2±3.8%) were significantly higher than that of TCP group (2.7±1.4%). Significantly more bone cells in the new bone occurred in sites transplanted with BMAC (552±257) and PRP (491±211) compared to TCP alone (187±94). But the difference between the treatment groups was not significant. Both human BMACs and PRP may provide therapeutic benefits in bone tissue engineering applications. These fractions possess a similar ability to enhance early-phase bone regeneration.
登录
查看更多内容
DOI：
10.1016/j.ijom.2005.12.007
发表时间：
2006-06-01
影响因子：
2.4
作者：
Hibi, H;Yamada, Y;Endo, Y
通讯作者：
Endo, Y
影响因子：
6.7
作者：
Pieri, Francesco;Lucarelli, Enrico;Marchetti, Claudio
通讯作者：
Marchetti, Claudio
影响因子：
6.1
作者：
Ouyang Xiang-ying;Qiao Jing
通讯作者：
Qiao Jing
影响因子：
4.3
作者：
Piemontese, Matteo;Aspriello, Simone Domenico;Procaccini, Maurizio
通讯作者：
Procaccini, Maurizio
影响因子：
4.1
作者：
Kretlow, James D.;Spicer, Patrick P.;Mikos, Antonios G.
通讯作者：
Mikos, Antonios G.